Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and understanding the ...
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...
Aspirin has been shown to effectively reduce recurrence rates and improve disease-free survival,” said Anna Martling, MD, PhD.
JonesTrading analyst Soumit Roy maintained a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of ...
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...
The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...
(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following ...
Avec 1.019 interventions en 2024, soit 58 de moins par rapport à 2023, le bilan de l’activité des sapeurs pompiers d’Argenton ...
The approval by the NMPA was based on data from the confirmatory Phase IIIb clinical trial in patients with MET exon 14 skipping alteration NSCLC (NCT04923945). Preliminary efficacy and safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback